Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ASP2408 in Healthy Subjects
NCT02150070Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP2408 in rheumatoid arthritis (RA) (6 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 2 more. Started Aug 2011; status: completed.
02
Drugs
ASP2408
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02150070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150070.